Trial Profile
A phase I study of icotinib combined with whole brain radiotherapy in non-small-cell-cancer patients with brain metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jul 2016
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Jul 2016 New trial record
- 07 Jun 2016 Results assessing neurocognitive and quality-of-life analysis presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.